REXAHN PHARMACEUTICALS DEF 14A 6-14-2010

Company

Opus Genetics, Inc.

Filed

April 26, 2010

Period of Report

June 14, 2010

Accession Number

0001140361-10-017500

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →